Play all audios:
Verve Therapeutics said Tuesday its one-time treatment that uses the “base editing” form of CRISPR to remove a cholesterol-associated gene in monkeys has demonstrated durable and significant
reductions in LDL “bad” cholesterol for six months. Based on these new data, Verve intends to advance the treatment, called VERVE-101, into clinical development for people born with
heterozygous familial hypercholesterolemia, or HeFH, a genetic heart disease that causes lifelong, high LDL levels “These individuals have sky-high LDL starting at birth and they have a
tremendously high exposure to cumulative LDL, which is their primary problem,” said Sekar Kathiresan, Verve’s co-founder and CEO. “Verve-101 will look to be a definitive therapy for them — a
one-and-done permanent lowering of cholesterol, or a genetic medicine for a genetic disease.” STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+
SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All
Plans To read the rest of this story subscribe to STAT+. Subscribe